Hsu, Cheng-Chieh http://orcid.org/0000-0002-3423-7159
Shao, Baohai
Kanter, Jenny E.
He, Yi
Vaisar, Tomas
Witztum, Joseph L.
Snell-Bergeon, Janet
McInnes, Gregory http://orcid.org/0000-0002-8033-2499
Bruse, Shannon
Gottesman, Omri
Mullick, Adam E. http://orcid.org/0000-0003-4600-961X
Bornfeldt, Karin E. http://orcid.org/0000-0001-9208-6523
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R35HL150754, P01HL151328, R01HL161829)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
American Heart Association (#828090)
Article History
Received: 12 August 2022
Accepted: 4 January 2023
First Online: 13 February 2023
Competing interests
: A.E.M. is employed by Ionis Pharmaceuticals. O.G., S.B. and G.M. are employed by Empirico Inc. K.E.B. serves on the scientific advisory board of Esperion Therapeutics, Inc. J.L.W. receives royalties from US patents 9,075,050 B2, 6716410B1, 9,347,959, 11,008,381 B2, 11,008 82 B2 and 11,168,148 B2 on oxidation-specific antibodies and biomarkers related to oxidized lipoproteins held by UCSD. J.L.W. is a cofounder of Oxitope, Inc. and Kleanthi Diagnostics, LLC, and is a consultant for Ionis Pharmaceuticals. The other authors declare no competing interests.